The PIK3CA is a crucial CRC treatment biomarker, because CRC patients with PIK3CA mutation were found to be less responsive to EGFR inhibition, while their survival rates can be increased with the use of aspirin [8,40]. Here, EGFR is linked to colorectal carcinoma.